04.08.14
A generic equivalent of Lovaza (Omega-3-Acid Ethyl Esters Capsules, USP), has been approved in the U.S. In a statement from Teva Pharmaceutical Industries Ltd., Jerusalem, Israel, the company believes it is first-to-file and thus far is the only company to receive an approval from FDA. It plans to commence shipping immediately.
Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the U.S., according to IMS data as of December 2013.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Its branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics.
Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the U.S., according to IMS data as of December 2013.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries. Its branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics.
